BI-1206 clinical trials
Also written BI-1206.
How each study uses BI-1206 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BI-1206 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI-1206
- 2
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test BI-1206.
- Sep 2027A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLPhase 1/2 · BioInvent International AB
- Nov 2027A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsPhase 1/2 · BioInvent International AB
Studies
Open first, then newest update. How each study uses BI-1206 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLRecruitingPhase 1/2BioInvent International ABNCT03571568Written as BI-1206How we know
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsRecruitingPhase 1/2BioInvent International ABNCT04219254Written as BI1206How we know
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedPhase 1/2Cancer Research UKNCT02933320Written as BI-1206 single agent dose escalation phaseHow we know
Codes
What other systems call BI-1206 · ClinicalTrials.gg INT014416
- UNII (FDA) 24S6PA0WXWBI-1206One source FDA
- NCI Thesaurus C156458Anti-CD32B Monoclonal Antibody BI-1206One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 24S6PA0WXW | BI-1206 | One source FDA |
| NCI Thesaurus | C156458 | Anti-CD32B Monoclonal Antibody BI-1206 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.